Neurocrine Reports Added NBI-98854 Data Will Be Presented at APA Meeting

Neurocrine Biosciences, Inc.

announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia clinical trials of valbenazine will be presented at the American Psychiatric Association Annual Meeting in May. The four posters will include an evaluation of the impact of valbenazine on the psychiatric stability of subjects with underlying schizophrenia, schizoaffective disorder or mood disorder (including bipolar disorder or major depressive disorder), data assessing the effect of valbenazine stratified by baseline tardive dyskinesia severity, and an evaluation of valbenazine with concomitant antipsychotic use. The APA Annual Meeting is the largest international conference of psychiatrists and behavioral health specialists, bringing together an estimated 13,000 clinicians and scientists to address current topics in psychiatry. Valbenazine data will be presented at the APA Annual Meeting poster sessions at the following dates and times: Monday May 16th 2pm-4pm Tardive Dyskinesia and Valbenazine (NBI-98854) Response as a Function of Concomitant Antipsychotic Use Tuesday May 17th 2pm-4pm Valbenazine (NBI-98854) is Effective for Treating Tardive Dyskinesia in Individuals with Schizophrenia or Mood Disorder KINECT 3: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia Psychiatric Stability Maintained in Tardive Dyskinesia Subjects Treated with Valbenazine (NBI-98854) "We are very pleased to have four abstracts accepted for presentation at the American Psychiatric Association Annual Meeting in Atlanta in May. This meeting, coupled with our American Academy of Neurology presentations in April, demonstrates to health care providers the breadth and depth of our tardive dyskinesia clinical data across multiple treatment paradigms," said Chris O'Brien, M.D., Chief Medical Officer at Neurocrine. "We have submitted seven abstracts between the American Academy of Neurology and the American Psychiatric Association Annual Meetings and all seven have been accepted; evidence of the consistency, quality and strength of the data emerging from our clinical program."